PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jcinvestThe Journal of Clinical InvestigationCurrent IssueArchiveSubscriptionAbout the Journal
 
J Clin Invest. 1990 January; 85(1): 62–67.
PMCID: PMC296387

Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response.

Abstract

Adjuvant intravesical Calmette-Guerin bacillus (BCG) is an effective treatment for superficial bladder cancer. The mechanisms by which BCG mediates antitumor activity are not known. We investigated the initial interaction of BCG with the bladder mucosa to determine whether binding was essential for the development of antitumor activity. Herein, we show that bladder urothelial disruption induced by acrolein, adriamycin, or electrocautery resulted in BCG binding in areas of urothelial damage. Binding induced by each method was inhibited by anti-fibronectin (FN) antibodies but not by antibodies to the basement membrane component laminin. Intravesical BCG binding also was inhibited by pretreating BCG with soluble FN. Inhibition of intravesical FN-mediated BCG attachment prevented immunization via the intravesical route. Moreover, the expression of both delayed hypersensitivity in the bladder of BCG-immunized mice and antitumor activity was inhibited by blocking FN-mediated intravesical BCG attachment. These data suggest that intralumenal attachment of BCG appears to be mediated by FN. Moreover, these data suggest that intravesical FN mediated attachment of BCG is a requisite step in BCG-mediated antitumor activity in the murine bladder tumor model.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.5M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976 Aug;116(2):180–183. [PubMed]
  • Herr HW, Pinsky CM, Whitmore WF, Jr, Sogani PG, Oettgen HF, Melamed MR. Experience with intravesical bacillus Calmette-Guèrin therapy of superficial bladder tumors. Urology. 1985 Feb;25(2):119–123. [PubMed]
  • Brosman SA. Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol. 1982 Jul;128(1):27–30. [PubMed]
  • Mori K, Lamm DL, Crawford ED. A trial of bacillus Calmette-Guérin versus adriamycin in superficial bladder cancer: a South-West Oncology Group Study. Urol Int. 1986;41(4):254–259. [PubMed]
  • FREUND J. The mode of action of immunologic adjuvants. Bibl Tuberc. 1956;(10):130–148. [PubMed]
  • BIOZZI G, BENACERRAF B, GRUMBACH F, HALPERN BN, LEVADITI J, RIST N. Etude de l'activité granulopexique du système réticulo-endothélial au cours de l'infection tuberculeuse expérimentale de la souris. Ann Inst Pasteur (Paris) 1954 Sep;87(3):291–300. [PubMed]
  • Fey F, Arnold W, Graffi A. Demonstration of the stimulation of the reticulohistiocytic system (RHS) of mice by treatment with BCG by means of biometric and histochemical techniques. Eur J Cancer. 1976 Aug;12(8):595–598. [PubMed]
  • Bast RC, Bast BS. Critical review of previously reported animal studies of tumor immunotherapy with nonspecific immunostimulants. Ann N Y Acad Sci. 1976;277(00):60–93. [PubMed]
  • Pang AS, Morales A. BCG induced murine peritoneal exudate cells: cytotoxic activity against a syngeneic bladder tumor cell line. J Urol. 1982 Jun;127(6):1225–1229. [PubMed]
  • Ratliff TL, Gillen D, Catalona WJ. Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. J Urol. 1987 Jan;137(1):155–158. [PubMed]
  • Reichert DF, Lamm DL. Long term protection in bladder cancer following intralesional immunotherapy. J Urol. 1984 Sep;132(3):570–573. [PubMed]
  • Shapiro A, Ratliff TL, Oakley DM, Catalona WJ. Reduction of bladder tumor growth in mice treated with intravesical Bacillus Calmette-Guérin and its correlation with Bacillus Calmette-Guérin viability and natural killer cell activity. Cancer Res. 1983 Apr;43(4):1611–1615. [PubMed]
  • Lamm DL, Thor DE, Stogdill VD, Radwin HM. Bladder cancer immunotherapy. J Urol. 1982 Nov;128(5):931–935. [PubMed]
  • Kelley DR, Haaff EO, Becich M, Lage J, Bauer WC, Dresner SM, Catalona WJ, Ratliff TL. Prognostic value of purified protein derivative skin test and granuloma formation in patients treated with intravesical bacillus Calmette-Guerin. J Urol. 1986 Feb;135(2):268–271. [PubMed]
  • Haaff EO, Catalona WJ, Ratliff TL. Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG. J Urol. 1986 Oct;136(4):970–974. [PubMed]
  • Ratliff TL, Palmer JO, McGarr JA, Brown EJ. Intravesical Bacillus Calmette-Guérin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guérin. Cancer Res. 1987 Apr 1;47(7):1762–1766. [PubMed]
  • Ratliff TL, Kavoussi LR, Catalona WJ. Role of fibronectin in intravesical BCG therapy for superficial bladder cancer. J Urol. 1988 Feb;139(2):410–414. [PubMed]
  • Pommier CG, Inada S, Fries LF, Takahashi T, Frank MM, Brown EJ. Plasma fibronectin enhances phagocytosis of opsonized particles by human peripheral blood monocytes. J Exp Med. 1983 Jun 1;157(6):1844–1854. [PMC free article] [PubMed]
  • See WA, Chapman PH. Heparin prevention of tumor cell adherence and implantation on injured urothelial surfaces. J Urol. 1987 Jul;138(1):182–186. [PubMed]
  • Thomas WR, Schrader JW. Delayed hypersensitivity in mast-cell-deficient mice. J Immunol. 1983 Jun;130(6):2565–2567. [PubMed]
  • Collins FM, Mackaness GB. The relationship of delayed hypersensitivity to acquired antituberculous immunity. I. Tuberculin sensitivity and resistance to reinfection in BCG-vaccinated mice. Cell Immunol. 1970 Sep;1(3):253–265. [PubMed]
  • Mosesson MW, Amrani DL. The structure and biologic activities of plasma fibronectin. Blood. 1980 Aug;56(2):145–158. [PubMed]
  • Click EM, Balian G. Domain structure of human plasma and cellular fibronectin. Use of a monoclonal antibody and heparin affinity to identify three different subunit chains. Biochemistry. 1985 Nov 5;24(23):6685–6696. [PubMed]
  • Mosher DF. Physiology of fibronectin. Annu Rev Med. 1984;35:561–575. [PubMed]
  • Hynes RO, Yamada KM. Fibronectins: multifunctional modular glycoproteins. J Cell Biol. 1982 Nov;95(2 Pt 1):369–377. [PMC free article] [PubMed]
  • Kuusela P, Vartio T, Vuento M, Myhre EB. Attachment of staphylococci and streptococci on fibronectin, fibronectin fragments, and fibrinogen bound to a solid phase. Infect Immun. 1985 Oct;50(1):77–81. [PMC free article] [PubMed]
  • Espersen F, Clemmensen I. Isolation of a fibronectin-binding protein from Staphylococcus aureus. Infect Immun. 1982 Aug;37(2):526–531. [PMC free article] [PubMed]
  • Courtney HS, Simpson WA, Beachey EH. Binding of streptococcal lipoteichoic acid to fatty acid-binding sites on human plasma fibronectin. J Bacteriol. 1983 Feb;153(2):763–770. [PMC free article] [PubMed]
  • Vercellotti GM, Lussenhop D, Peterson PK, Furcht LT, McCarthy JB, Jacob HS, Moldow CF. Bacterial adherence to fibronectin and endothelial cells: a possible mechanism for bacterial tissue tropism. J Lab Clin Med. 1984 Jan;103(1):34–43. [PubMed]
  • Vaudaux P, Suzuki R, Waldvogel FA, Morgenthaler JJ, Nydegger UE. Foreign body infection: role of fibronectin as a ligand for the adherence of Staphylococcus aureus. J Infect Dis. 1984 Oct;150(4):546–553. [PubMed]
  • Gardiner RA, Seymour GJ, Lavin MF, Strutton GM, Gemmell E, Hazan G. Immunohistochemical analysis of the human bladder. Br J Urol. 1986 Feb;58(1):19–25. [PubMed]
  • Pode D, Alon Y, Horowitz AT, Vlodavsky I, Biran S. The mechanism of human bladder tumor implantation in an in vitro model. J Urol. 1986 Aug;136(2):482–486. [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation